Prosight Management’s 2seventy bio TSVT Stock Holding History

Prosight Management’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-42,537	Closed	-$434K	–	47
2023 Q1	$434K	Buy	+42,537	New	+$486K	0.21%	35

Other funds holding TSVT

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prosight Management's TSVT Position: Q2 2023 in Review

Prosight Management sold out of 2seventy bio (TSVT) in Q2 2023, closing a stake of 42,537 shares — an estimated $434K sold.

Prosight Management first reported a position in TSVT in Q1 2023 and held it in 1 quarter. The position peaked at $434K in Q1 2023. 149 funds tracked by Wall St. Rank hold TSVT as of Q2 2023.

Prosight Management reported no remaining 2seventy bio position as of Q2 2023 after selling out during the quarter.
Prosight Management sold 42,537 2seventy bio shares in Q2 2023, an estimated $434K.
Prosight Management first reported a position in 2seventy bio in Q1 2023 and held it in 1 quarter.
Prosight Management's 2seventy bio position peaked at $434K in Q1 2023.
149 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2023.

Based on Prosight Management's 13F filing for Q2 2023, filed 14 Aug 2023.